A study to evaluate virologic responses of patients with HCV genotype (GT) 1 infection receiving Ledipasvir/Sofosbuvir (LDV/SOF) with or without ribavirin (RBV) therapy
Phase of Trial: Phase IV
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 11 Jan 2017 Results assessing virologic response (n=1021) published in the Drugs.
- 17 Apr 2016 Status changed from active, no longer recruiting to completed, according to the results published.
- 17 Apr 2016 Efficacy results (n=1091) presented at The International Liver Congress™ 2016.